Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Svetlana A Hopkins"'
Autor:
Robert V House, Thomas A Broge, Todd J Suscovich, Doris M Snow, Milan T Tomic, Genevieve Nonet, Kamaljit Bajwa, Guangyu Zhu, Zachary Martinez, Kyal Hackett, Christopher G Earnhart, Nicole M Dorsey, Svetlana A Hopkins, Dalia S Natour, Heather D Davis, Michael S Anderson, Melicia R Gainey, Ronald R Cobb
Publikováno v:
PLoS ONE, Vol 17, Iss 6, p e0267796 (2022)
The current global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a public health crisis with more than 168 million cases reported globally and more than 4.5 million deaths at the time of writ
Externí odkaz:
https://doaj.org/article/540dec6f055d46d19a5e609a29bf6fc3
Autor:
Nicole M. Dorsey, Svetlana A. Hopkins, Joseph P. Nkolola, Milan T. Tomic, Robert H. Carnahan, Laura A. VanBlargan, Michael S. Diamond, James C. Slaughter, James E. Crowe, Ronald R. Cobb, Doris M Snow, Abishek Chandrashekar, Dan H. Barouch, Robert V. House, Brian Hoppe, Manuel Hechenblaickner, Laura Collins, Kyal Hackett, Christopher G. Earnhart, Pavlo Gilchuk, Rita E. Chen, Genevieve H. Nonet
Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention, post-exposure prophylaxis, or therapy. However, the titer of neutralizing antibodies required for protection against SARS-CoV-2 infection remains poorly characterized.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::981e5aefbd432a1890922c0ede7a0898
https://doi.org/10.1101/2021.09.27.462074
https://doi.org/10.1101/2021.09.27.462074
Autor:
Ronald R. Cobb, Joseph Nkolola, Pavlo Gilchuk, Abishek Chandrashekar, Jingyou Yu, Robert V. House, Christopher G. Earnhart, Nicole M. Dorsey, Svetlana A. Hopkins, Doris M. Snow, Rita E. Chen, Laura A. VanBlargan, Manuel Hechenblaickner, Brian Hoppe, Laura Collins, Milan T. Tomic, Genevieve H. Nonet, Kyal Hackett, James C. Slaughter, Mark G. Lewis, Hanne Andersen, Anthony Cook, Michael S. Diamond, Robert H. Carnahan, Dan H. Barouch, James E. Crowe
Publikováno v:
Med (New York, N.y.)
Background Human monoclonal antibody (mAb) treatments are promising for COVID-19 prevention or therapy. The pre-exposure prophylactic efficacy of neutralizing antibodies that are engineered with mutations to extend their persistence in human serum an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c0f94566208584434067a873dac3809
https://doi.org/10.1016/j.medj.2022.01.004
https://doi.org/10.1016/j.medj.2022.01.004